摘要
免疫检查点抑制剂致药物性肝损伤(checkpoint inhibitor-induced liver injury,ChILI)通常发生率为1.72%~30%,临床表现具有异质性,严重时可导致肝衰竭甚至死亡,及时识别和干预可显著改善预后。近年来ChILI的诊断、评估、治疗和预防领域进展迅速,本文阐述上述进展,旨在提高本病的临床诊疗水平并为未来研究方向提供借鉴。
Checkpoint inhibitor-induced liver injury(ChILI)typically occurs at a rate of 1.72%-30%.Its clinical manifestations are heterogeneous and can lead to severe outcomes,including liver failure and death.Timely recognition and intervention significantly improve prognosis.In recent years,rapid progress has been made in the diagnosis,assessment,treatment,and prevention of ChILI.This review aims to summarize these advancements to enhance clinical management of the condition and provide insights for future research directions.
作者
张端敏
于岩岩
徐小元
徐京杭
Zhang Duanmin;Yu Yanyan;Xu Xiaoyuan;Xu Jinghang(Department of Infectious Diseases,Peking University First Hospital,Beijing 100034,China)
出处
《中国医学前沿杂志(电子版)》
北大核心
2025年第6期21-27,共7页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
关键词
免疫检查点抑制剂
肝损伤
诊断
治疗
预防
肝毒性
Immune checkpoint inhibitors
Liver injury
Diagnosis
Treatment
Prevention
Hepatotoxicity
